5. "Full Market Awareness" A professional relations company and consulting firm Contact: Sean McDonald smcdonald@acornmanagementpartners.com 941 . 208.3919 Atlanta,Georgia & Sarasota,Florida Disclaimer Notice: The information contained in this e-mail message and its attachments is intended solely for the use of the individual(s) to whom it is addressed and may contain information that is the confidential information of Acorn Management Partners L.L.C. ("AMP") and its subsidiaries. The Information may be about companies in which A.M.P has or may receive compensation in the future. Any material in this message should be considered as ADVERTISEMENT ONLY. Please consult with a certified financial advisor before making any investment decisions. All information on this report should be confirmed before making an investment decision. Acorn Management Partners L.L.C. ("AMP") and its subsidiaries, and any affiliates and information providers make no implied or express warranties on the information provided. This is not to be construed as a solicitation to buy or sell securities. As with any stock, the featured companies involve a high degree of risk and volatility, and all investors/advisors should know that they may lose a portion or all of their investment if they decide to purchase any stock. Acorn Management Partners L.L.C. ("AMP"), its affiliates, associates, relatives and anyone associated with in any manner reserves the right to either buy or sell shares in the profiled company's stock. The Securities and Exchange Commission has compiled an extensive amount of information concerning investing, including the inherent risks involved. We encourage our readers to visit the SEC's website to acquire this important information. Safe Harbor Dis- closure: Acorn Management Partners L.L.C. ("AMP") website publications may contain or incorporate by reference "forward- looking statements, including certain information with respect to plans and strategies of the featured company. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward- looking statements. Without limiting the forgoing, the words "believe(s)," "anticipate(s)," "plan(s)," "expect(s)," "project(s)" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual events or actual results of the Companies profiled herein to differ materially from these indicated by such forward-looking statements. Certain statements contained herein constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business and financing, business trends, future operating revenues and expenses. Although the Company believes that the statements are reasonable, it can give no assurances that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the Company or contained in any and/or all profile/ research reports, contain no guarantee of future performance, and that the actual result may differ materially from those set forth in the forward-looking statements. Difference in results can be caused by various fa ctors including, but not limited to, the Company's ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. Any statements that express or involve discussions with respect to predictions, expectat ions, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking stat ements in this action may be identified through the use of words such as "expects," "will," "anticipates," "estimates," "believes," "may," or by statements indicating certain actions "may," "could," or "might" occur. We encourage our readers to invest carefully and review all forms of investments and read the investor information. More information please visit http:// www.sec.gov and/or (FINRA) at: http://www.FINRA.com. Readers can review all public filings by compan ies at the SEC's EDGAR page. The FINRA has published information on how to invest carefully at its web s ite.

4. Continue Reading for Our Disclosure... Ken d’Entremont Chief Executive Officer and Director Ken d’Entremont is the founder, president, and CEO of Medexus Inc. Previously, he was the general manager and vice president of business development at Sanofi, where he led the in- licensing initiatives for Sanofi Canada. Mr. d’Entremont holds a Bachelor of Science in Chemistry from McMaster University Marcel Konrad Chief Financial Officer Mr. Konrad joined Medexus in 2021 from CareDx, Inc. (Nasdaq: CDNA), a precision medicine solutions company, where he served as SVP Finance & Accounting and VP, Corporate Controller. He brings over 20 years of experience in Accounting, Finance and Business across various global markets including CFO at Santen Inc, a US subsidiary of Santen Pharmaceuticals, and various roles at Novartis both in the US and Switzerland. Mr. Konrad was an Auditor with KPMG. He holds an International MBA from the University of San Diego and has an MBA from HEC Lausanne, Switzerland. Mr. Konrad is an active US CPA. Michael Adelman General Manager, U.S. Operations Michael Adelman joined Medexus in 2020 from Aptevo Therapeutics, where he led all commercial functions as SVP, Commercial Operations. Mr. Adelman has over 25 years of life-science commercial experience, including leadership roles at Emergent BioSolutions, Cangene, Adolor, and AstraZeneca. Mr. Adelman holds a Bachelor of Science in Finance from Northeastern University and Master of Business Administration from New York University’s Stern School of Business. Richard Labelle Vice President Allergy, Pediatric and OTC Portfolios, Canadian Operations Richard Labelle joined Medexus (Pediapharm legacy) in February of 2014. Previously he was the general manager and vice president of the consumer portfolio at Sanofi. He has held several management positions including heading commercial operations for the cardiovascular and osteoporosis divisions. He also led the business development team at Aventis. Mr. Labelle holds a Bachelor of Commerce from University of Quebec and a Master of Business Administration from McGill – HEC executive program. Kerry Bakewell Vice President Specialty Markets, Canadian Operations Kerry Bakewell joined Medexus in January of 2002, as Director of Sales and Marketing. She has over 30 years of experience in the pharmaceutical industry, including several management positions at Merck Frosst and Sanofi. She has played an integral role in the growth and success of the Specialty Markets Division in Canada. Miss Bakewell holds a Bachelor of Science degree from The University of Alberta Management Team:

3. Continue Reading for Management Background & Our Disclosure... Recent News • Treosulfan NDA Resubmitted to FDA • Medexus Generates Revenue of US$76.7 Million in Fiscal Year 2022 and US$20.3 million in Fiscal Q4 (Strongest Q4 Revenue in Company History) o Achieved adjusted EBITDA* of $1.1 million in fiscal Q4 2022 compared to $(1.6) million in fiscal Q4 2021 and $1.9 million in fiscal Q3 2022. o Delivered total revenue of $20.3 million in fiscal Q4 2022, an increase of 15% compared to fiscal Q4 2021 and, as expected, a decrease of 5% compared to fiscal Q3 2022 partly due to a large order in late fiscal Q3 2022 originally anticipated in fiscal Q4 2022. • Medexus Pharmaceuticals Announces Resubmission of Treosulfan NDA • Medexus Pharmaceuticals Announces Deal for Gleolan in the United States • Medexus Pharmaceuticals Announces Normal Course Issuer Bid, or NCIB, for Convertible Debentures o Medexus will implement a NCIB in respect of its 6% unsecured convertible debentures due 2023 • Medexus Announces Expanded Availability of Trecondyv® (Treosulfan) in Canada Financial results: (fiscal year ends March 2022) - Bloom Burton - Canaccord Genuity - Mackie Research - Roth Capital - Stifel GMP - Prasath Pandurangan - Tania Gonsalves - Andre Uddin - Scott Henry - Justin Keywood Analyst Coverage:

2. Continue Reading for Recent News , Management Background and Our Disclosure ... The leading prescription products are Rasuvo® and Metoject® , a unique formulation of methotrexate (auto-injector and pre-filled syringe designed to treat rheumatoid arthritis and other auto-immune diseases ), Rupall® , an innovative allergy medication with a unique mode of action , and IXINITY® , a control for the prevention of bleeding episodes in adults and children above 10 who suffer from Hemophilia B. Product Portfolio IXINITY® Product Profile  Strong safety profile  Mean incremental recovery: 98%  Mean terminal half-life: 24 hours Growth Opportunities:  $1B US Market  4-5000 US Patients • Pediatric indication could increase market by ~30% • >4% Market Share Currently o ~17% of patients will switch per year for increased efficacy Rupall TM (Canada) Profile  Newest prescription allergy medication in growing market  Unique Dual Mode of Action Growth Opportunities:  Patients switching from generics and OTC products have caused dramatic increase in demand (prescription market is growing at a 18.1% annualized rate*)  33% year over year unit demand growth (Sept 2021 MAT*) , in year 5 of launch. Treosulfan (U.S. & Canada)  Medexu s ha s inlicensed treosulfan from Medac Pharma fo r commercializatio n in North America  First i n a ne w conditioning treatment c la ss for allogeneic hematopoietic stem cell transplantation  Announced Resubmission of Treosulfan Growth Opportunities :  Recently approved by Health Canada and commercially launched under the brand name Trecondyv®  Potential 7.5-year exclusivity in the U.S. upon approval under the Orphan Drug Act  Current market leading product in the U.S. generated $126M revenue prior to genericization, while being used off-label  Clear Path to FDA Decision Following medac’s Type A Meeting with FDA

1. AMP Quick Facts Medexus Pharmaceuticals Inc . ( OTC QX : MEDXF ) Acorn Management Partners, LLC August 202 2 OTCQX : MEDXF Price: $ 1. 57 Date: 0 8 / 0 7 / 2 2 Fiscal Year: 03 /3 1/22 MKT Cap: ~ $ 3 0 . 93 m C.O.H*: ~ $ 10.02 m Inside Ownership: ~ 10 .01 % S/O*: ~ 19. 9 5 m Float: ~ 1 6 . 57 m AVG Vol.: ~ 5 . 29 k For More Information Please Contact: Brandon Bouysou b randon@acornmanagement partners.com Industry: Healthcare Drug Manufacturers - Specialty & Generic * As of most recent filing Continue Reading for More Information, Recent News, Management Background & Our Disclosure... Medexus Pharmaceuticals Medex us Pharmaceuticals, Inc. i s a leading innovative and rare disease , specialty pharmaceutical company wi t h a strong North America n commercial platform. Medexu s is currently focused on the multi-billion dollar therapeutic areas of rheumatology , auto-immune disease , sp ecialty oncology an d pediatrics . Business Model Medexu s aim s to leverage t hei r medical knowledge, North American commercial infrastructure and drug commercialization expertise , to su pply and addre ss unmet m edical needs. • Focuse d o n North American Innovative & Rare Disease Pharmaceuticals • Focused o n commercial and late-stage pharmaceutical products • • Growing organicall y throug h expanding market share, commercial scale launche s, an d increased reimbursements Highly scalable busine ss model with North American infrastructure and salesforce already i n place The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Collaboration. - Medexus Institutiona l Ownership: ~ 6.86 %